USPTO Refuses Again To Reissue Lipitor PatentThe USPTO has again rejected (second time) Pfizer ’s request to reissue US5273995 (995’), which covers enantiomer of Atorvatatin as product. The verdict gives Ranbaxy who has 180 days first to file Para IV exclusivity hope to launch the cholesterol-lowering drug Lipitor as early as March 2010. (link to financial express news).
The basic patent which covers Atorvastatin racemate 893' is also under reexamination by USPTO on the opposition filed by a lawfirm representing Ranbaxy.
